Armata Pharmaceuticals, Inc. (ARMP)Healthcare | Biotechnology | Los Angeles, United States | NYSE American
5.37 USD
-0.06
(-1.105%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 5.37 |
Hot Take ↕ | Aug. 22, 2026, 4:48 a.m. EDT
The investment case here is severely compromised by deteriorating fundamentals. The company is burning through cash rapidly, evidenced by massive negative free cash flow and operating cash flow, while holding a debt load nearly 13 times its total cash reserves. This precarious balance sheet is reflected in the crushing valuation metrics, including a negative book value and a forward P/E that implies perpetual losses. Despite a recent uptick in share price and a 'strong buy' analyst recommendation driven by potential clinical trial data, the underlying business is hemorrhaging capital. The options market confirms this skepticism, with traders aggressively buying protection against a drop rather than betting on a rally. Until the company demonstrates a clear path to profitability or a substantial reduction in its debt burden, the risk of permanent capital loss outweighs any speculative upside. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.161006 |
| MSTL | 0.294435 |
| AutoARIMA | 0.302842 |
| AutoETS | 0.302901 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 30.45 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.206 |
| Excess Kurtosis | -0.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.152 |
| Market Cap | 199,667,232 |
| Forward P/E | -2.80 |
| Beta | 1.33 |
| Previous Name | Armata Pharmaceuticals Inc. |
| Website | https://www.armatapharma.com |
As of Aug. 22, 2026, 4:48 a.m. EDT: Speculators are positioning defensively with heavy open interest in out-of-the-money puts (OTM) relative to calls, creating a significant put/call ratio imbalance that suggests a bearish bias. While there is some call volume at strikes significantly above the current price, the overwhelming majority of option activity is concentrated in protective puts, indicating a fear of further downside rather than a strong bullish conviction.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.1294117 |
| Address1 | 5,005 McConnell Avenue |
| All Time High | 1,960,000.0 |
| All Time Low | 0.83 |
| Ask | 5.39 |
| Ask Size | 100 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 113,040 |
| Average Daily Volume3 Month | 153,970 |
| Average Volume | 153,970 |
| Average Volume10Days | 113,040 |
| Beta | 1.329 |
| Bid | 5.28 |
| Bid Size | 200 |
| Book Value | -6.223 |
| City | Los Angeles |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.37 |
| Current Ratio | 0.109 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 5.445 |
| Day Low | 4.985 |
| Display Name | Armata Pharmaceuticals |
| Dividend Date | 1,557,446,400 |
| Earnings Timestamp End | 1,794,427,200 |
| Earnings Timestamp Start | 1,794,427,200 |
| Ebitda | -33,448,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -14.64 |
| Enterprise To Revenue | 88.34 |
| Enterprise Value | 489,668,224 |
| Eps Forward | -1.92 |
| Eps Trailing Twelve Months | -5.29 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 310 665 2963 |
| Fifty Day Average | 5.196 |
| Fifty Day Average Change | 0.17399979 |
| Fifty Day Average Change Percent | 0.033487257 |
| Fifty Two Week Change Percent | 112.94117 |
| Fifty Two Week High | 16.34 |
| Fifty Two Week High Change | -10.97 |
| Fifty Two Week High Change Percent | -0.67135864 |
| Fifty Two Week Low | 2.4 |
| Fifty Two Week Low Change | 2.9699998 |
| Fifty Two Week Low Change Percent | 1.2374998 |
| Fifty Two Week Range | 2.4 - 16.34 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 769,440,600,000 |
| Float Shares | 11,902,323 |
| Forward Eps | -1.92 |
| Forward P E | -2.796875 |
| Free Cashflow | -27,409,624 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 61 |
| Fullday Change | -0.0599999 |
| Fullday Change Percent | -1.10497 |
| Fullday Price | 5.37 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -2.17355 |
| Gross Profits | -12,048,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.67639 |
| Held Percent Institutions | 0.13452 |
| Implied Shares Outstanding | 37,181,979 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.ampliphibio.com/phoenix.zhtml?c=84981&p=irol-stockquote |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,557,446,400 |
| Last Split Factor | 1:14 |
| Long Business Summary | Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc. |
| Long Name | Armata Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 199,667,232 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_84546611 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -192,178,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 201,898,145 |
| Number Of Analyst Opinions | 2 |
| Open | 5.37 |
| Operating Cashflow | -25,420,000 |
| Operating Margins | -4.10837 |
| Payout Ratio | 0.0 |
| Phone | 310 665 2928 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 5.37 |
| Post Market Time | 1,787,959,804 |
| Prev Name | Armata Pharmaceuticals Inc. |
| Previous Close | 5.43 |
| Price Hint | 2 |
| Price To Book | -0.8629278 |
| Price To Sales Trailing12 Months | 36.02151 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.106 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0599999 |
| Regular Market Change Percent | -1.10497 |
| Regular Market Day High | 5.445 |
| Regular Market Day Low | 4.985 |
| Regular Market Day Range | 4.985 - 5.445 |
| Regular Market Open | 5.37 |
| Regular Market Previous Close | 5.43 |
| Regular Market Price | 5.37 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 49,659 |
| Return On Assets | -0.25832 |
| Revenue Growth | 0.157 |
| Revenue Per Share | 0.152 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 37,181,979 |
| Shares Percent Shares Out | 0.0225 |
| Shares Short | 834,737 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 704,657 |
| Short Name | Armata Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.074200004 |
| Short Ratio | 5.48 |
| Source Interval | 15 |
| State | CA |
| Symbol | ARMP |
| Target High Price | 20.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 17.5 |
| Target Median Price | 17.5 |
| Total Cash | 23,952,000 |
| Total Cash Per Share | 0.644 |
| Total Debt | 313,952,992 |
| Total Revenue | 5,543,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.29 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.5433 |
| Two Hundred Day Average Change | -2.1733003 |
| Two Hundred Day Average Change Percent | -0.28811002 |
| Type Disp | Equity |
| Volume | 49,659 |
| Website | https://www.armatapharma.com |
| Zip | 90,066 |